Sobetirome (GC-1) is a thyroid hormone receptor β (TRβ)-selective agonist with liver uptake selectivity; it reduces high-density lipoprotein (HDL) cholesterol and very low-density lipoprotein (VLDL) triglyceride levels in euthyroid mice; lowers HDL cholesterol and triglyceride levels in hypercholesterolemic mice; increases hepatic HDL receptors and stimulates bile acid synthesis in hypercholesterolemic mice; and modulates fat mass, with 10× dosage resulting in only 21% fat mass gain (1.7 g) and 20× dosage inducing a 20% reduction in fat mass (1.3 g).